Association of WinRho® SDF (Rho(D) Immune Globulin (Human) with Intravascular Hemolysis (IVH) in the treatment of Immune Thrombocytopenic Purpura (ITP)

Pharmaforte updates healthcare professionals on the risk of IVH and its complications with WinRho® SDF when used in ITP. IVH can lead to severe anaemia and multi-organ failure including acute respiratory distress syndrome. From March 1995 to March 2009, 180 cases of IVH with WinRho® SDF have been reported worldwide. A disproportionate number of IVH cases were reported in patients with ITP secondary to hematological malignancies (leukemia or lymphoma) or active viral infections with HCV and EBV. Elderly patients with co-morbidities are more likely to experience renal and cardiovascular complications including fatal outcomes, from hemolysis. Physicians are encouraged to discuss the risks and benefits of WinRho® SDF and to alert patients about the signs and symptoms of IVH.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.